The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1595
ISSUE1595
April 6, 2020
Intravenous Cetirizine (Quzyttir) for Acute Urticaria
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Intravenous Cetirizine (Quzyttir) for Acute Urticaria
April 6, 2020 (Issue: 1595)
Quzyttir (TerSera), an IV formulation of the second-generation
H1-antihistamine cetirizine, has been
approved by the FDA for treatment of acute urticaria in
patients ≥6 months old. Oral formulations of cetirizine
(Zyrtec, and others) have been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.